

TSH Biopharm working together with InnoPharmax and Shandong Newtime Pharmaceutical enter into global agreement of

2020/07/08

TSH Biopharm (8432) and InnoPharmax today(7/8) announced granting Shandong Newtime Pharmaceutical an exclusive rights to commercialize pipeline product CRTA04, a treating chronic heart failure of ischemic agent in worldwide.

TSH and InnoPharmax successfully improved GSK' s product, Dilatrend/Coreg from twice tablet per day to once daily slow-released tablet. CRTA04 has been granted several patents from US, China, Taiwan etc. This collaboration aligns the interests and strengths of TSH and InnoPharmax and Shandong Newtime in actions designed to secure regulatory approval and commercializing CRTA04 in the world. Shandong Newtime will continue to be responsible for development and registration of CRTA04. CRTA04 is developed through the 505(b)(2) regulatory pathway and expect to get approval within one year after related clinical trial completed.

According to the agreement, TSH will receive part of total RMB 45million by milestone.

TSH Biopharm is dedicating to medicines development and innovation in chronic diseases field and continue developing other related health products, especially focusing on cardiovascular, gastrointestinal, and autoimmune diseases. Through self-development and co-development products, TSH Biopharm will keep providing economic treatment plan to gain more welfare for chronic patients.